BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38068896)

  • 1. High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study.
    Catalano R; Altieri B; Angelousi A; Arosio M; Bravi F; Canu L; Croci GA; Detomas M; Esposito E; Ferrante E; Ferrero S; Fuss CT; Kaltsas G; Kimpel O; Landwehr LS; Luconi M; Morelli V; Nesi G; Nozza E; Sbiera S; Serban AL; Ronchi CL; Mantovani G; Peverelli E
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
    Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
    Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
    Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
    Wang C; Sun Y; Wu H; Zhao D; Chen J
    Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining.
    Gan W; Han X; Gong Y; Yang Y; Wang C; Zhang Z
    Diagn Pathol; 2024 May; 19(1):71. PubMed ID: 38802933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
    Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
    Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.
    Romero Arenas MA; Whitsett TG; Aronova A; Henderson SA; LoBello J; Habra MA; Grubbs EG; Lee JE; Sircar K; Zarnegar R; Scognamiglio T; Fahey TJ; Perrier ND; Demeure MJ
    Ann Surg Oncol; 2018 Mar; 25(3):801-807. PubMed ID: 29218429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
    Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
    Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular basis of adrenocortical cancer.
    Lehmann T; Wrzesinski T
    Cancer Genet; 2012 Apr; 205(4):131-7. PubMed ID: 22559973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma.
    Kamai T; Murakami S; Arai K; Ishida K; Kijima T
    Cancer Sci; 2022 Jul; 113(7):2368-2377. PubMed ID: 35467062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
    Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological study of adrenocortical carcinoma with special reference to the Weiss system and TNM staging and the role of immunohistochemistry to differentiate it from renal cell carcinoma.
    Mondal SK; Dasgupta S; Jain P; Mandal PK; Sinha SK
    J Cancer Res Ther; 2013; 9(3):436-41. PubMed ID: 24125979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
    Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
    Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
    Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
    J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes.
    Parianos C; Kyriakopoulos G; Kostakis ID; Nasiri-Ansari N; Aggeli C; Dimitriadi A; Angelousi A; Papavassiliou AG; Kaltsas GA; Zografos G; Kassi E
    Horm Metab Res; 2021 Nov; 53(11):709-716. PubMed ID: 34740271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma.
    Gu Y; Gu W; Dou J; Lu Z; Ba J; Li J; Wang X; Liu H; Yang G; Guo Q; Zang L; Chen K; Du J; Pei Y; Mu Y
    Front Endocrinol (Lausanne); 2019; 10():226. PubMed ID: 31040822
    [No Abstract]   [Full Text] [Related]  

  • 20. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours.
    Schmitt A; Saremaslani P; Schmid S; Rousson V; Montani M; Schmid DM; Heitz PU; Komminoth P; Perren A
    Histopathology; 2006 Sep; 49(3):298-307. PubMed ID: 16918977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.